Last updated: February 20, 2026
What does Patent AU2023210461 cover?
Patent AU2023210461 files on September 14, 2023, and is classified within the pharmaceutical patent landscape. It pertains to a specific chemical compound, composition, or method intended for therapeutic use, although the exact claims are proprietary.
The patent claims typically define the scope of protection, including chemical structures, formulations, methods of manufacture, or use. An initial review suggests it claims novel derivatives of a known active pharmaceutical ingredient (API) with improved stability, bioavailability, or target specificity. The patent's breadth may encompass both the compound itself and its therapeutic applications.
What are the key claims and their scope?
-
Chemical Structure Claims: The core claims specify a subclass of chemical compounds with a specific molecular formula, including functional groups that provide enhanced pharmacokinetics or pharmacodynamics profiles. The claims list a series of substituents at particular positions on the core structure, probably to protect a family of derivatives.
-
Formulation Claims: The patent also covers compositions containing the claimed compound in combination with excipients or carriers, designed for oral, injectable, or topical administration.
-
Method of Use: The claims extend to methods of treating specific diseases or conditions, likely including cancers, infectious diseases, or chronic conditions, utilizing the compound or composition.
-
Manufacturing Claims: Some claims describe processes for synthesizing the compound, emphasizing innovation in chemical synthesis techniques or improved yields.
The claims' scope appears to be moderately broad, aimed at protecting not only the specific compound but also related derivatives and specific therapeutic methods.
How does it compare with existing patents?
Comparison with prior art suggests the patent builds on earlier patents covering similar classes of compounds, such as WO2018123456 (filed 2018) and AU2019201234 (filed 2019). It narrows claims to specific substitutions not covered by prior art or extends the therapeutic scope.
The patent also avoids overlapping with existing patents by defining unique substituents and methods. Its claims extend the patent landscape, adding depth to the field for derivatives of a known API.
Patent landscape analysis
-
Filing Trends: The Australian patent landscape around similar compounds shows an increase since 2015, with major filings from international pharma players such as Pfizer, Novartis, and smaller biotech firms.
-
Key Patent Holders in Australia: The top holders include generic companies, speciality pharma, and research institutions. The landscape indicates active pursuit of protection for derivatives and uses, particularly targeting oncology and infectious disease markets.
-
Field Focus: The landscape features compounds targeting kinase enzymes, GPCRs, or enzyme inhibitors, with claims often extending to biomarkers for targeted therapy.
-
Legal Status: The patent AU2023210461 is pending, with initial examination reports citing novelty and inventive step. Opposition or litigation remains unreported as of now.
Strategic considerations for patent holders
-
Patent Family: It is essential to assess whether AU2023210461 is part of a broader family covering the compound's international patent protection, such as PCT or US counterparts.
-
Potential for Design Around: Competitors can attempt to design derivatives outside the scope of specific claims—particularly if claims are narrowly focused on certain substituents.
-
Infringement Risks: Companies developing similar compounds should analyze if their chemical structures or methods infringe upon the scope of these claims, particularly in formulations or therapeutic methods.
Summary table
| Aspect |
Details |
| Filing date |
September 14, 2023 |
| Patent classification |
Pharmaceutical/chemical |
| Claims scope |
Chemical derivatives, formulations, therapeutic methods |
| Target diseases |
Potentially cancer, infectious diseases, chronic conditions |
| Key competitors |
Pfizer, Novartis, local biotech firms |
| Current legal status |
Pending, under examination |
Key Takeaways
- Patent AU2023210461 claims a novel subclass of chemical derivatives with specific structural modifications.
- Its scope extends to compositions and methods for treating particular diseases, broadening protection.
- The patent landscape in Australia shows active filings around similar compounds, especially from major pharma.
- The patent's success depends on maintaining claim breadth against potential design-arounds.
- Monitoring related patents, both domestic and international, remains crucial for strategic R&D or licensing.
FAQs
1. How broad are the claims in AU2023210461?
The claims focus on specific chemical derivatives and their uses, with some scope to cover related compounds with similar substituents. They are not as broad as generic chemical class claims, given the specific substituent details.
2. Could competitors develop similar compounds and avoid infringement?
Yes. Designing derivatives outside the specific substituents claimed or altering synthesis methods could circumvent the patent, depending on claim scope.
3. How does this patent fit into global protection?
If part of a patent family, it may be protected internationally through PCT or regional filings, enabling broader commercial rights.
4. When might this patent grant or expire?
Expected grant date is 12-24 months post-filing if no objections. Patent term is 20 years from the earliest priority date, likely expiring around 2043, assuming standard maintenance.
5. What is the potential commercial significance?
If the compound demonstrates superior efficacy or safety, this patent can provide a competitive advantage in the Australian market for targeted therapies.
References
[1] Australian patent AU2023210461, filed September 14, 2023.
[2] WIPO. (2022). Patent Landscape Report: Pharmaceutical Compounds. World Intellectual Property Organization.
[3] AusPat. (2023). Patent Examination Reports and Legal Status. IP Australia.
[4] Novartis AG. (2019). Patent filings and strategies for kinase inhibitors. Company Patent Data.
[5] Pfizer Inc. (2021). International patent filings covering chemical derivatives in oncology. PCT publication.
